360 related articles for article (PubMed ID: 36831674)
21. Prospects of molecularly-targeted therapies for cervical cancer treatment.
de Freitas AC; Gomes Leitão Mda C; Coimbra EC
Curr Drug Targets; 2015; 16(1):77-91. PubMed ID: 25479546
[TBL] [Abstract][Full Text] [Related]
22. Reduced MHC Class I and II Expression in HPV-Negative vs. HPV-Positive Cervical Cancers.
Evans AM; Salnikov M; Tessier TM; Mymryk JS
Cells; 2022 Dec; 11(23):. PubMed ID: 36497170
[TBL] [Abstract][Full Text] [Related]
23. HPV-specific immunotherapy: key role for immunomodulators.
Van de Wall S; Nijman HW; Daemen T
Anticancer Agents Med Chem; 2014 Feb; 14(2):265-79. PubMed ID: 24237218
[TBL] [Abstract][Full Text] [Related]
24. Molecular Approaches Target to Immunotherapy for HPV-Associated Cancers.
Zhang L; Zhou F; Zhao KN
Curr Cancer Drug Targets; 2017; 17(6):512-521. PubMed ID: 27993116
[TBL] [Abstract][Full Text] [Related]
25. Molecular pathogenesis of cervical cancer.
Ibeanu OA
Cancer Biol Ther; 2011 Feb; 11(3):295-306. PubMed ID: 21239888
[TBL] [Abstract][Full Text] [Related]
26. Advances in peptide-based human papillomavirus therapeutic vaccines.
Liu TY; Hussein WM; Toth I; Skwarczynski M
Curr Top Med Chem; 2012; 12(14):1581-92. PubMed ID: 22827526
[TBL] [Abstract][Full Text] [Related]
27. Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies.
Bhattacharjee R; Das SS; Biswal SS; Nath A; Das D; Basu A; Malik S; Kumar L; Kar S; Singh SK; Upadhye VJ; Iqbal D; Almojam S; Roychoudhury S; Ojha S; Ruokolainen J; Jha NK; Kesari KK
Crit Rev Oncol Hematol; 2022 Jun; 174():103675. PubMed ID: 35381343
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus infection and cervical cancer in Brazil: a retrospective study.
Cavalcanti SM; Deus FC; Zardo LG; Frugulhetti IC; Oliveira LH
Mem Inst Oswaldo Cruz; 1996; 91(4):433-40. PubMed ID: 9070405
[TBL] [Abstract][Full Text] [Related]
29. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
30. Cervical adenocarcinoma: moving towards better prevention.
Seoud M; Tjalma WA; Ronsse V
Vaccine; 2011 Nov; 29(49):9148-58. PubMed ID: 21983356
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus as an independent risk factor of invasive cervical and endometrial carcinomas in Jordan.
Abu-Lubad MA; Jarajreh DA; Helaly GF; Alzoubi HM; Haddadin WJ; Dabobash MD; Albataineh EM; Aqel AA; Alnawaiseh NA
J Infect Public Health; 2020 Apr; 13(4):613-618. PubMed ID: 31519382
[TBL] [Abstract][Full Text] [Related]
32. Human papilloma virus 16-18 infection and cervical cancer in Mexico: a case-control study.
Hernández-Avila M; Lazcano-Ponce EC; Berumen-Campos J; Cruz-Valdéz A; Alonso de Ruíz PP; Gonźalez-Lira G
Arch Med Res; 1997; 28(2):265-71. PubMed ID: 9204620
[TBL] [Abstract][Full Text] [Related]
33. Cervical cancer in Ethiopia: a review of the literature.
Derbie A; Mekonnen D; Nibret E; Misgan E; Maier M; Woldeamanuel Y; Abebe T
Cancer Causes Control; 2023 Jan; 34(1):1-11. PubMed ID: 36242682
[TBL] [Abstract][Full Text] [Related]
34. From the Infection to the Immunotherapy in Cervical Cancer: Can We Stop the Natural Course of the Disease?
Luvero D; Lopez S; Bogani G; Raspagliesi F; Angioli R
Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33050484
[TBL] [Abstract][Full Text] [Related]
35. Carcinogenesis Associated with Human Papillomavirus Infection. Mechanisms and Potential for Immunotherapy.
Vonsky M; Shabaeva M; Runov A; Lebedeva N; Chowdhury S; Palefsky JM; Isaguliants M
Biochemistry (Mosc); 2019 Jul; 84(7):782-799. PubMed ID: 31509729
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer.
Ding H; Zhang J; Zhang F; Xu Y; Yu Y; Liang W; Li Q
Front Oncol; 2022; 12():990877. PubMed ID: 36300095
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and Distribution of Human Papillomavirus Genotypes (1997-2019) and Their Association With Cervical Cancer and Precursor Lesions in Women From Southern Mexico.
Alarcón-Romero LDC; Organista-Nava J; Gómez-Gómez Y; Ortiz-Ortiz J; Hernández-Sotelo D; Del Moral-Hernández O; Mendoza-Catalán MA; Antaño-Arias R; Leyva-Vázquez MA; Sales-Linares N; Antonio-Véjar V; Illades-Aguiar B
Cancer Control; 2022; 29():10732748221103331. PubMed ID: 35608056
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Human Papillomavirus (HPV) Vaccines: A Novel Approach.
Kawana K; Adachi K; Kojima S; Kozuma S; Fujii T
Open Virol J; 2012; 6():264-9. PubMed ID: 23341862
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus, cervical cancer, and the vaccines.
Tovar JM; Bazaldua OV; Vargas L; Reile E
Postgrad Med; 2008 Jul; 120(2):79-84. PubMed ID: 18654072
[TBL] [Abstract][Full Text] [Related]
40. HES1 Protein Modulates Human Papillomavirus-Mediated Carcinoma of the Uterine Cervix.
Tripathi R; Rath G; Sharma V; Hussain S; Sharma S; Bharadwaj M; Mehrotra R
J Glob Oncol; 2019 Jan; 5():1-10. PubMed ID: 30615540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
